PMID- 11441328
OWN - NLM
STAT- MEDLINE
DCOM- 20011025
LR  - 20191105
IS  - 1075-2765 (Print)
IS  - 1075-2765 (Linking)
VI  - 8
IP  - 4
DP  - 2001 Jul-Aug
TI  - Allergen-induced inflammation and the role of immunoglobulin E (IgE).
PG  - 291-7
AB  - The prevalence of common allergic disorders such as asthma, allergic rhinitis, 
      and atopic dermatitis has increased significantly in the past 30 years. The 
      impact of these atopic diseases on the patient and the health care system is 
      considerable: Allergic disorders are associated with a high degree of morbidity, 
      which can profoundly impact patient quality of life and health care resource use. 
      Existing strategies to treat allergic disorders beyond simple allergen avoidance 
      focus on diminishing or eliminating the recurrent and/or persistent signs and 
      symptoms that characterize the allergic response. A new strategy has been 
      developed that uses antibodies directed against immunoglobulin E (IgE) to prevent 
      it from binding to cells bearing its receptors and thus neutralizing the allergic 
      response before it begins. These new agents reduce allergic responses in atopic 
      individuals and improve their symptoms while reducing rescue medication and 
      corticosteroid use in patients with allergic asthma or seasonal allergic 
      rhinitis. Thus, anti-IgE antibodies represent proof that IgE plays a central role 
      in allergic reactions and that anti-IgE therapy is a potentially effective 
      treatment for allergic disease.
FAU - Fendrick, A M
AU  - Fendrick AM
AD  - University of Michigan Medical Center, Division of General Medicine, Ann Arbor, 
      MI 48109-0429, USA. amfen@umich.edu
FAU - Baldwin, J L
AU  - Baldwin JL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Anti-Allergic Agents/pharmacology/therapeutic use
MH  - Antibodies, Anti-Idiotypic/pharmacology/therapeutic use
MH  - Antigen-Antibody Reactions/immunology
MH  - Desensitization, Immunologic
MH  - Humans
MH  - Hypersensitivity, Immediate/*immunology/*therapy
MH  - Immunoglobulin E/biosynthesis/drug effects
MH  - Inflammation/*immunology
RF  - 52
EDAT- 2001/07/07 10:00
MHDA- 2001/10/26 10:01
CRDT- 2001/07/07 10:00
PHST- 2001/07/07 10:00 [pubmed]
PHST- 2001/10/26 10:01 [medline]
PHST- 2001/07/07 10:00 [entrez]
AID - 10.1097/00045391-200107000-00011 [doi]
PST - ppublish
SO  - Am J Ther. 2001 Jul-Aug;8(4):291-7. doi: 10.1097/00045391-200107000-00011.